Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | ACACA | Q13085 | 1/20 | 0.30 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549858 | 1.00 | STK17B (0.38) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL16076736 | 0.99 | STK17B (0.37) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL30926497 | 0.99 | STK17B (0.37) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL20926952 | 0.93 | STK17B (0.36) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL18493681 | 0.91 | STK17B (0.40) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL21014691 | 0.90 | PIK3CD (0.32) | SCN9ACYP3A4GSK3BDYRK1ACKS1B | |
| SCHEMBL20980308 | 0.90 | STK17B (0.35) | STK17BSTK17ASCN9ACYP3A4GSK3B | |
| SCHEMBL20980306 | 0.90 | STK17B (0.35) | STK17BSTK17ASCN9ACYP3A4GSK3B | |
| SCHEMBL25957164 | 0.89 | STK17B (0.40) | STK17BSTK17ASCN9ACYP3A4SCN10A | |
| SCHEMBL16036398 | 0.89 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | G1 THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | G1 THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | PHARMACOSMOS A/S (DK) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | STK17B 986/4885STK17A 957/4885SCN9A 4502/4885 |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | STK17B 852/4885STK17A 1072/4885SCN9A 4451/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | STK17B 1802/4885STK17A 1642/4885SCN9A 4818/4885 |
| US-11446295-B2 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | CDK4, RB1, BTK | STK17B 676/4885STK17A 835/4885SCN9A 3976/4885 |
| US-20220175780-A1 | TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS | RB1, CDK4, CDK6 | STK17B 852/4885STK17A 1072/4885SCN9A 4451/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | STK17B 1245/4885STK17A 1696/4885SCN9A 4426/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | STK17B 676/4885STK17A 835/4885SCN9A 3976/4885 |
| US-11654148-B2 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | RB1, CDK4, CDKN1A | STK17B 986/4885STK17A 957/4885SCN9A 4502/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | STK17B 1245/4885STK17A 1696/4885SCN9A 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.